<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240413061475N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-14</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of Acupressure and Buzzy on First insertion success and pain related insertion of intravenous catheter (Angiocath)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Acupressure and Buzzy on First insertion success and pain related insertion of intravenous catheter (Angiocath) in 3-6 year old children referred to the emergency department</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/77779</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Convenience sampling will be used for this study. This means that any individual who enters the treatment center and meets the study's inclusion criteria will be eligible to participate. With a sample size of 84, we aim to recruit 28 participants in each group. We also intend to ensure an equal distribution of girls and boys in each experimental group. Therefore, we will employ a blocked randomization method.

We will use blocks of 12 participants each, assigning 4 to the Buzzy group, 4 to the Acupressure group, and 4 to the Control group. There will be three blocks of 12 for girls and three blocks of 12 for boys. Additionally, we will use two additional blocks of 6 to enroll an additional 12 girls and boys. In each block of 6, 2 participants will be assigned to the Acupressure group, 2 to the Buzzy group, and 2 to the Control group.

Random allocation will be conducted using the "Random Allocation Software". Each child who comes to the clinic for angiocatheter placement and meets the study's inclusion criteria will be placed in one of these blocks based on gender and will be randomly assigned to one of the interventions
From the start of the vascular access process and angiocatheter placement, the research assistant measures the time to vascular access using a stopwatch and records it along with the number of attempts to access the vessels in the clinical data collection checklist. Simultaneously, by carefully observing the child, the assistant enters scores for facial expression, leg movement, activity level, crying, and consolability to assess the pain score in the aforementioned checklist. All interventions are performed outside the venipuncture room and the research assistant is blinded to the type of intervention performed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: pain related insertion of intravenous catheter (Angiocath). Condition 2: first insertion success of intravenous catheter (Angiocath).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:The first intervention group : Acupressure. Intervention 2: Intervention group:The second intervention group: buzzy. Intervention 3: Control group: Control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals.

When:
The start of the access period after the publication of the article

To whom:
All people

Conditions:
The data can be used with the permission of Dr. Ali Asghar Jesemi Marghzar.

Where to obtain:
Send an email to Dr. Ali Asghar Jesemi Marghzar
Email address: jesmiaa@gmail.com

How to obtain:
By sending an email to Dr. Ali Asghar Jasemi Marghzar after his approval, the data will be provided to the individual.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Asghar Jesmi Marghzar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sabzevar, Shohadaye Hasteiee Boulevard, Sabzevar University of Medical Science</address>
        <city>sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613873136</zip>
        <telephone>+98 51 4401 1300</telephone>
        <email>jesmiaa@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Asghar Jesmi Marghzar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sabzevar, Shohadaye Hasteiee Boulevard, Sabzevar University of Medical Science</address>
        <city>sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613873136</zip>
        <telephone>+98 51 4401 1300</telephone>
        <email>jesmiaa@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>There is a need and a doctor's order to insert the IV catheter
The child is 3 to 6 years of age
Parents have given informed consent.
This is the child's first IV catheterization experience at this case of admission
The child is fully alert
The child does not have acute or chronic pain, and the child's FLACC pain scale score is zero upon admission</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>IV catheter to be inserted in a place other than the back of the hand
Usage of sedatives or topical or oral pain relievers within 48 hours before insertion
There is bruising, inflammation, wound or fracture near the IV catheterization place or the massage point.
The child has a history of chemotherapy and dialysis.
The child has cognitive disorders.
Specific medical conditions: (blood disorders, thyroid disorders, epilepsy, peripheral vascular disease, diabetes, peripheral neuropathy, edema, blood diseases, mental health problems, hearing and vision problems, motor problems in the lower extremities)
Hearing and vision impairments
Inability to communicate verbally
Intellectual disability or cerebral palsy
Diagnosed mental health problem</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:The first intervention group : Acupressure</i_keyword>
      <i_keyword>Intervention group:The second intervention group: buzzy</i_keyword>
      <i_keyword>Control group: Control group</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>FLACC instrument pain score. Timepoint: During the intervention. Method of measurement: FLACC instrument pain score(faces, legs, activity, cry, consolability ).</prim_outcome>
      <prim_outcome>Number of successful angiocath placement attempts. Timepoint: During the intervention. Method of measurement: Counting the number of times of angiocath placement.</prim_outcome>
      <prim_outcome>Time of successful angiocath placement attempts. Timepoint: During the intervention. Method of measurement: stopwatch.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-06</approval_date>
        <contact_name>Ethics committees of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Sohadaye hastei boulevard - Sabzevar university of medical Sciences Campus sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
